Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Key Points
The executive sold 7,576 shares.
The transaction resulted in a 7% reduction in the insider's direct equity holdings.
The sale was executed directly by the reporting owner under a Rule 10b5-1 trading plan.
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $373,000 |
| Shares sold | 7,576 |
| Post-transaction shares (directly held) | 102,193 |
| Post-transaction value | $5.1 million |
Transaction value based on SEC Form 4 weighted average sale price ($49.23); post-transaction value based on Aug. 17, 2026, market close ($49.85).
Key questions
- What is the significance of the Rule 10b5-1 plan for this transaction?
The sale was conducted under a trading plan adopted on May 15, 2026, which established a predetermined schedule for the disposal three months before the trade was executed. - How much direct equity does Christian Todd Nichols retain in the company?
Following this transaction, the executive continues to hold approximately 102,000 shares directly, representing an insider ownership stake of 0.06%. - What was the market valuation of the security at the time of the sale?
The shares were sold at a weighted average price of $49.23, while the stock was valued at $49.85 at the market close on the day of the transaction. - How does this sale compare to the insider's total holdings?
The liquidation of 7,576 shares reduced the reporting owner's direct position from 109,769 shares to 102,193 shares, reflecting routine portfolio management.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-14) | $49.06 |
| Market Capitalization | $7.9 billion |
| Revenue (TTM) | $1.7 billion |
| Net Income (TTM) | $66.1 million |
Company Snapshot
- Alkermes develops and commercializes proprietary pharmaceutical products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder, and other neurological conditions, generating revenue through the sale of these commercial products and pipeline candidates in development.
- The company operates a biopharmaceutical business model focused on research, development, and commercialization of therapeutic solutions that address unmet medical needs in neuropsychiatric and neurological disorders across multiple geographic markets.
- Alkermes serves healthcare providers, patients, and healthcare systems in the United States, Ireland, and internationally, with a primary focus on treating patients with serious mental illness and substance use disorders.
Alkermes is a Dublin-headquartered biopharmaceutical company with a market capitalization of $7.9 billion and TTM revenues of $1.7 billion, positioning it as a significant player in the neuropsychiatric therapeutics space. The company maintains a diversified portfolio of commercial products and clinical-stage candidates, with a strategic focus on addressing high-prevalence conditions including opioid dependence, alcohol use disorder, and schizophrenia. Alkermes' competitive differentiation is anchored in its proprietary drug delivery technologies and sustained focus on underserved patient populations in mental health and addiction medicine.
What this transaction means for investors
Alkermes is off to a strong start in 2026. For the six months ended June 30, it reported $888.9 million in revenue, an increase from $697.2 million in the prior-year period. The stock price has also performed well, climbing 63.6% over the last 12 months. In comparison, the S&P 500 is up 19.3% in the same period. For Nichols, this was a pre-planed transaction, so it appears to be just selling to take some profits off the table after the stock has performed so well. Although he sold approximately 7,500 shares, he still directly holds more than 102,000 shares. Selling the amount of shares he did doesn't raise any alarm bells, and as it was a pre-planned sale, this shouldn't worry shareholders.
Analysts are typically bullish on what's ahead for Alkermes. Of the 17 covering the stock, 71% rate it a buy, 24% a hold, and 6% a sell, according to CNN. Among those analysts, the median one-year price target is $59, representing a 24.4% gain from today's price. The highest price target in the group is $72, while the lowest is $38.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alkermes Plc. The Motley Fool has a disclosure policy.